NCT03987958 - A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

August 8, 2019

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions

Acute Myeloid Leukemia

Trial Locations (12)

13100

COMPLETED

ZIV Medical Center /ID# 229211, Safed

91031

ACTIVE_NOT_RECRUITING

Shaare Zedek Medical Center /ID# 228016, Jerusalem

91120

ACTIVE_NOT_RECRUITING

Hadassah /ID# 213356, Jerusalem

1834111

ACTIVE_NOT_RECRUITING

HaEmek Medical Center /ID# 213370, Afula

3109601

ACTIVE_NOT_RECRUITING

Rambam Health Care Campus /ID# 213355, Haifa

3339419

ACTIVE_NOT_RECRUITING

Bnai Zion Medical Center /ID# 213344, Haifa

4428164

RECRUITING

Meir Medical Center /ID# 213352, Kfar Saba

4941492

ACTIVE_NOT_RECRUITING

Rabin Medical Center /ID# 213343, Haifa

5265601

ACTIVE_NOT_RECRUITING

The Chaim Sheba Medical Center /ID# 213353, Ramat Gan

6423906

ACTIVE_NOT_RECRUITING

Tel Aviv Sourasky Medical Center /ID# 213354, Tel Aviv

6971028

ACTIVE_NOT_RECRUITING

Assuta Tel Aviv Medical Center /ID# 213371, Tel Aviv

8443901

ACTIVE_NOT_RECRUITING

Soroka University Medical Center /ID# 213369, Beersheba